ketoconazole has been researched along with Infections, Staphylococcal in 8 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double masked, placebo controlled clinical trial, of topical 2% ketoconazole cream with lid hygiene, for the treatment of seborrhoeic and mixed seborrhoeic/staphylococcal blepharitis was conducted." | 9.06 | Ketoconazole in the treatment of blepharitis. ( Blatchford, NR; Midgley, G; Nelson, ME, 1990) |
| "Eumycetoma is a chronic progressive disabling and destructive inflammatory disease which is commonly caused by the fungus Madurella mycetomatis." | 6.79 | The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection. ( Fahal, AH; Mahgoub, el S; Mhmoud, NA; van de Sande, WW, 2014) |
| "A double masked, placebo controlled clinical trial, of topical 2% ketoconazole cream with lid hygiene, for the treatment of seborrhoeic and mixed seborrhoeic/staphylococcal blepharitis was conducted." | 5.06 | Ketoconazole in the treatment of blepharitis. ( Blatchford, NR; Midgley, G; Nelson, ME, 1990) |
| "Eumycetoma is a chronic progressive disabling and destructive inflammatory disease which is commonly caused by the fungus Madurella mycetomatis." | 2.79 | The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection. ( Fahal, AH; Mahgoub, el S; Mhmoud, NA; van de Sande, WW, 2014) |
| " Combined with good oral bioavailability (F = 42." | 1.43 | Discovery of Potent Benzofuran-Derived Diapophytoene Desaturase (CrtN) Inhibitors with Enhanced Oral Bioavailability for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. ( Chen, F; Di, H; Lan, L; Li, J; Lu, Y; Sheng, C; Wang, X; Wang, Y; Wei, H; Xiao, Q; Xu, Y; Zhang, L; Zhu, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xiao, ZP | 1 |
| Ma, TW | 1 |
| Liao, ML | 1 |
| Feng, YT | 1 |
| Peng, XC | 1 |
| Li, JL | 1 |
| Li, ZP | 1 |
| Wu, Y | 1 |
| Luo, Q | 1 |
| Deng, Y | 1 |
| Liang, X | 1 |
| Zhu, HL | 1 |
| Wang, Y | 2 |
| Chen, F | 3 |
| Di, H | 2 |
| Xu, Y | 3 |
| Xiao, Q | 2 |
| Wang, X | 2 |
| Wei, H | 3 |
| Lu, Y | 3 |
| Zhang, L | 2 |
| Zhu, J | 3 |
| Sheng, C | 1 |
| Lan, L | 3 |
| Li, J | 3 |
| Ni, S | 1 |
| Li, B | 1 |
| Liu, Y | 1 |
| Chen, W | 1 |
| Qiu, X | 1 |
| Li, X | 1 |
| Liu, W | 1 |
| Hu, L | 1 |
| Lin, D | 1 |
| Wang, M | 1 |
| Zheng, X | 1 |
| Mao, F | 1 |
| Block, SL | 1 |
| Mhmoud, NA | 1 |
| Fahal, AH | 1 |
| Mahgoub, el S | 1 |
| van de Sande, WW | 1 |
| Nelson, ME | 1 |
| Midgley, G | 1 |
| Blatchford, NR | 1 |
| Selden, ST | 1 |
2 trials available for ketoconazole and Infections, Staphylococcal
| Article | Year |
|---|---|
The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection.
Topics: Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antif | 2014 |
Ketoconazole in the treatment of blepharitis.
Topics: Adult; Aged; Aged, 80 and over; Blepharitis; Dermatitis, Seborrheic; Double-Blind Method; Eyelid Dis | 1990 |
6 other studies available for ketoconazole and Infections, Staphylococcal
| Article | Year |
|---|---|
Tyrosyl-tRNA synthetase inhibitors as antibacterial agents: synthesis, molecular docking and structure-activity relationship analysis of 3-aryl-4-arylaminofuran-2(5H)-ones.
Topics: Anti-Bacterial Agents; Enzyme Inhibitors; Furans; Gram-Positive Bacteria; Gram-Positive Bacterial In | 2011 |
Discovery of Potent Benzofuran-Derived Diapophytoene Desaturase (CrtN) Inhibitors with Enhanced Oral Bioavailability for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Bacterial Proteins; Benzofurans; Biological Av | 2016 |
Discovery of Benzocycloalkane Derivatives Efficiently Blocking Bacterial Virulence for the Treatment of Methicillin-Resistant S. aureus (MRSA) Infections by Targeting Diapophytoene Desaturase (CrtN).
Topics: Alkanes; Anti-Bacterial Agents; Antifungal Agents; Dose-Response Relationship, Drug; Drug Discovery; | 2016 |
Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Drug Resistance, Bacterial; Ether-A-Go-Go Potassi | 2017 |
Tricky triggers of intertrigo.
Topics: Acyclovir; Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Antiviral Agents; Candidiasis; C | 2014 |
Simultaneous treatment with rifampin and ketoconazole.
Topics: Dermatitis; Drug Therapy, Combination; Humans; Ketoconazole; Rifampin; Staphylococcal Infections; St | 1986 |